Contact:
4008465777
News & Events
-
04-22
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for novel triple-target inhibitor
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company”) received the acceptance notification...
-
04-15
Tonghua Dongbao reports YoY increase of 14.63% in annual net profit 2020
On the evening of April 15, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2020 annual report, disclosing that the Company...
-
03-05
Tonghua Dongbao partners WuXi AppTec to develop novel drugs
On March 5, 2021, Tonghua Dongbao and WuXi AppTec signed a strategic cooperation memorandum and a contract for the development of three Class 1 new diabetes drugs in Shanghai. Mr. Leng Chunsheng...
-
01-26
Tonghua Dongbao’s strategic partner Adocia reports positive clinical trial results for BC Lispro
On January 26 (Beijing time), Adocia, a biotechnology company focused on the treatment of diabetes and other metabolic diseases, announced positive results of its clinical trial of the ultra-rapid-acting insulin lispro...
-
01-21
Tonghua Dongbao plans to set up novel drug R&D center in Hangzhou
On the evening of January 21, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") announced that the Company plans to invest RMB...
-
01-14
Tonghua Dongbao reports annual net profit of RMB 929 million for 2020
On the evening of January 14, 2021, Tonghua Dongbao (600867) released a performance report which disclosed that the Company achieved operating revenue of RMB 2.925 billion, up 5.32% YoY, and a net profit attributable...